Zentalis Pharmaceuticals (ZNTL) Earnings Date & Reports

A.I. Advisor

published Earnings

ZNTL is expected to report earnings to fall 29.64% to -87 cents per share on November 06

Zentalis Pharmaceuticals ZNTL Stock Earnings Reports

Q3'24

Est.

$-0.87

Q2'24

Missed

by $0.40

Q1'24

Beat

by $0.91

Q4'23

Est.

$-0.86

Q3'23

Beat

by $0.13

The last earnings report on August 09 showed earnings per share of -124 cents, missing the estimate of -84 cents. With 911.30K shares outstanding, the current market capitalization sits at 266.65M.

View a ticker or compare two or three

Compare

ZNTL

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For ZNTL
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

View to see Real Time Patterns for ZNTL (Try 14 days for $1 only)

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

1359 Broadway

Phone

+1 212 433-3791

Employees

168

Web

https://www.zentalis.com